Avalo Therapeutics (AVTX) Cash from Operations Growth (1y) (2015 - 2026)
Avalo Therapeutics (AVTX) Cash from Operations Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 4.87% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -28.96% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.58% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -119.28% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 100.14% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 151.70% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 56.79% |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | -75.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -75.59% |
| Mar 31, 2026 | -87.16% |
| Dec 31, 2025 | 5.03% |
| Sep 30, 2025 | -42.38% |
| Jun 30, 2025 | 30.34% |
| Mar 31, 2025 | -52.48% |
| Dec 31, 2024 | -443.89% |
| Sep 30, 2024 | -68.62% |
| Jun 30, 2024 | -47.68% |
| Mar 31, 2024 | 38.30% |
| Dec 31, 2023 | 29.80% |
| Sep 30, 2023 | -219.39% |
| Jun 30, 2023 | 11.58% |
| Mar 31, 2023 | 37.44% |
| Dec 31, 2022 | 76.96% |
| Sep 30, 2022 | 135.15% |
| Jun 30, 2022 | 35.01% |
| Mar 31, 2022 | 12.28% |
| Dec 31, 2021 | -18.95% |
| Sep 30, 2021 | -37.24% |